glp 1 approved for heart disease GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies More GLP-1 news: in a

December 4th, 2025: New Study Links GLP-1 Drugs to Increased Incidence of Chronic Cough A peer-reviewed study published on November 26 in JAMA Otolaryngology Head & Neck Surgery reports that GLP-1 medications such as Ozempic and Mounjaro are associated with higher rates of chronic cough compared to several other second-line diabetes treatments

In December 2025, Eli Lilly submitted the drug to the FDA for weight loss and plans to submit it for type 2 diabetes in 2026

doi: 10.1038/s41467-019-09598-9 [DOI] [PMC free article] [PubMed] [Google Scholar] 88

Copper (GHK-CU) are said to include: stimulation of hyaluronic acid production, retaining moisture in the skin, firming and softening the skin, repairing cell damage, anti-inflammatory activity and antioxidant activity

Your dose may increase based on your response, but your monthly payment remains flatmeaning the 7-day half-life benefit and weekly convenience apply at every dose tier without higher costs

Gastroenterology 1993